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48 Poster Session-Ihas not been identified at the time of this report. Five patients are
alive (3–13 mo) while 1 patient died 12 mo. after CBT due to pneu-
monia.
Conclusion: Preliminary analysis suggests that ex vivo EXP in
MSC-CB is feasible and may provide rapid engraftment. Accrual
to the trial continues.123
CD41FOXP31 REGULATORY T CELLS MEDIATE SUPPRESSION OF COL-
ONY FORMING ACTIVITY OF LEUKEMIC AS WELL AS PRIMARY MYELOID
PROGENITORS
Urbieta, M., Levy, R.B. University of Miami Miller School of Medicine,
Miami, FL
CD41CD251Foxp31 regulatory T cells (Treg) are essential
intermediaries of peripheral self tolerance. The role of Treg as mod-
ulators of the adaptive and innate immune responses has been exten-
sively studied within the last decade. Our laboratory has previously
found that in addition to their ability to regulate such responses,
Treg cells also possess the capacity to inhibit the colony forming ac-
tivity of early hematopoietic progenitor cells (PC) of myeloid origin.
In vitro experiments demonstrated that co-cultures of bone marrow
PC with activated Tregs resulted in 60% decrease of CFU-IL3
levels. Suppression of CFU activity was contact dependent and in-
volved TGF-b1, a Treg cytokine with strong inhibitory properties
of early hematopoietic progenitors. To address the regulation by
Tregs on bone marrow PC in vivo, highly purified (.99.5%) Tregs
from B6-Foxp3gfp1 mice were co-infused with syngeneic bone
marrow into lethally irradiated, B6-wt recipients. Colony forming
activity of IL-3 sensitive myeloid progenitors was assessed one
week post-BMT and was significantly suppressed (p\0.02) in recip-
ients receiving co-infused Treg cells. Based on the ability to suppress
differentiation of primary hematopoietic PC populations, we hy-
pothesized that Tregs may also inhibit myeloid leukemia progenitor
populations. To test this hypothesis, the myeloid leukemia cell line
NFS-60 was examined. The expression of IL-3Ra on these leukemia
cells was confirmed by flow cytometry, consistent with their IL-3 de-
pendence for growth and survival. We co-cultured anti-CD3/CD28
activated Treg cells with NFS-60 cells for 2 days and examined their
CFU activity in rmIL3 supplemented methylcellulose cultures. Acti-
vated Tregs suppressed CFU levels  70%. This inhibition was
abolished in transwell cultures indicating the Treg effector activity
was contact dependent as observed for primary marrow progenitor
cell suppression. Addition of rTGF-b1 inhibited NSF-60 prolifera-
tion and experiments involving neutralization of bioactive TGF-b1
in Treg/NFS-60 co-cultures with mAb 1D11 are presently under-
way. We intend to investigate myeloid progenitor cell activity and
tumor cell proliferation in leukemia bearing recipients receiving au-
tologous hematopoietic cell transplants (HCT) together with Treg
populations.HISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES
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HIGH RISK OF GRAFT FAILURE IN PATIENTS WITH ANTI-HLA ANTI-
BODIES UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTA-
TION
Ciurea, S.O., de Lima, M., Cano, P., Korbling, M., McMannis, J.,
Giralt, S., Shpall, E.J., Champlin, R.E., Fernandez-Vina, M. The
University of Texas M.D. Anderson Cancer Center, Houston, TX
Background: Haploidentical stem cell transplantation
(HaploSCT) is associated with a graft failure (GF) rate of up to
20%, the causes of which are currently unknown. We hypothesized
that anti-HLA antibodies (HLA AB) directed against donor specific
antigens are contributing to the development of GF in such patients.
Methods: 22consecutivepatients,who receiveda total of 25haploi-
dentical transplants, were evaluated prospectively for the presence of
HLAAB.The conditioning regimen consisted offludarabine,melpha-
lan and thiotepa previously described. The presence of antibodies wasdetermined by testing the patients’ sera with a panel of fluorescent
beads coated with single HLA antigens using a Luminexe platform;
results were interpreted as fluorescence intensity (FI) with FI\500
negative, and 500–1500, 1500–3000 and.3000 considered weak, in-
termediate and strong, respectively. HLA A, B, C, DRB1, DRB3/4/
5, DQB1 and DPB1 were typed by high resolution methods.
Results: 6/22 patients experienced GF. Five patients, all females
with median age 39 years, had intermediate or strong FI antibody
titers, directed against both HLA class I and II antigens, most com-
monly anti-HLA DRB1. Overall, 4/6 (67%) HaploSCT performed
in the in the presence of HLA AB developed GF as compared with
1/19 (5%) patientswhodid not have antibodies (P5 0.001).Moreover,
all 4 patients (100%) receiving aHaploSCT in the presence ofmoder-
ate to high DSA titers failed to engraft (Table). Patients with GF un-
derwent second transplants from the same donors. After the first
patient was identified to have GF in the presence of HLA antibodies,
treatmentwith rituximab andplasma exchangewas initiated; this treat-
ment appeared todecrease the antibody titers in 2/4patients enough to
allow engraftment (Table). No significant differences were found in
the #CD341 cells infused, # allelemismatched, and # of bonemarrow
blasts at the time of transplant between the two groups. A review of the
pregnancy history (all patients with HLA antibodies were females)
showed that themedian number of pregnancies was 3 in theGF group
(N5 5) as compared with 0 in the control group (N5 6) (P5 0.1). In
addition, the transfusion history identified a median of 37 units (range
17–65) transfused in the GF group (N 5 5) as compared with 15 the
control group (range 4–38) (N5 16) (P5 0.007).
Conclusion: A high rate of graft rejection was observed among
patients with donor-derived anti-HLA antibodies receiving
a HaploSCT.
Relationship between HLA antibody titers and engraftment in
5 patients who received a total of 8 haploidentical transplants
at MDACC
TiterPt # AB type
Initial
titer R/PETiter
after
R/PE/
pre first
SCTEngrafted
Y/Nafter
first SCT/
pre
second
SCTEngrafted
Y/N1 A*3201 N/A N 1 1 1 N NT Y
2 A*0211/
B*391301/
Cw*0702/
DRB1*04041 1 1/
111/
111/
1Y 11/
11/NT/
1N 11/
111/
NT/1N3 DRB1*0701 11 Y - Y N/A N/A
4 DRB1*0701/
DRB4* 0101/
DQB1*020211/
111/
111Y 111/
111/
111N -/-/- Y5 DRB1*0401/
DRB4* 0103/
DPB1*040111/
11/
111Y 6/1/
111Y N/A N/AAB – antibody, R – rituximab, PE – plasma exchange, NT – not tested.125
FLUDARABINE, MELPHALAN AND THIOTEPA CONDITIONING FOR UNRE-
LATED DONOR CORD BLOOD TRANSPLANTATION
Ciurea, S.O., Kebriaei, P., Khouri, I., Qazilbash, M., Jones, R.,
Petropoulos, D., Worth, L.L., Alousi, A., Hosing, C., Cano, P.,
McMannis, J., Giralt, S., Fernandez-Vina, M., Shpall, E.J., de
Lima,M. University of TexasMDAnderson Cancer Center, Houston, TX
Cord blood transplantation (CBT) is an established therapy for
patients (pts) who lack a matched sibling or unrelated donor. How-
ever, the optimal type and intensity of the preparative regimen for
such pts is unclear. We studied a conditioning regimen consisting
of fludarabine, melphalan and thiotepa in adult pts receiving a CBT.
Methods: 37 pts, median age 31 years (2–57), median weight
73kg, with advanced hematologic malignancies (24 with acute leuke-
mia, 13 with lymphoma/CLL) were treated between 8/2003-5/2008.
